



Jordan E. Axelrad, MD, MPH
Associate Professor, Division of Gastroenterology and Hepatology,

Department of Medicine, NYU Grossman School of Medicine;
Co-Director, Inflammatory Bowel Disease Center at NYU Langone Health, NY

Dr. Jordan E. Axelrad is an Associate Professor of Medicine in the Division of Gastroenterology and Hepatology, Department of Medicine, at NYU Grossman School of Medicine, and Co-Director of the Inflammatory Bowel Disease Center at NYU Langone Health. Dr. Axelrad also directs the Clostridioides difficile and immunotherapy-related bowel diseases programs at NYU Langone Health. He attended Tufts University and then received his medical and public health degrees from Tufts University School of Medicine. He completed his internal medicine training at the Icahn School of Medicine at Mount Sinai in the Healthcare Leadership Track. He then went on to complete fellowship training in gastroenterology at Columbia University Irving Medical Center, serving as chief fellow. Following his training, he joined NYU Grossman School of Medicine as a physician-scientist to develop and lead an academic inflammatory bowel disease (IBD) program.

Dr. Axelrad received specialized training in clinical and IBD investigation. He has a particular interest in malignant and infectious complications of inflammatory bowel disease. He has examined the risk of incident cancer in patients with IBD and a history of prior cancer subsequently exposed to various immunosuppressive therapies, co-leading a national prospective registry. These studies helped shaped current guidelines and have provided critical guidance to patients. He is also focused on identifying environmental triggers of IBD and flares, including gastrointestinal infections. He has demonstrated that nearly one-third of IBD flares are complicated by a gastrointestinal infection, with a significant burden due to Clostridioides difficile. Focusing on the gut microbiome, he is dedicated to developing innovative microbial approaches and therapeutics to mitigate flares and even prevent IBD. Dr. Axelrad has received funding from the Crohn's and Colitis Foundation and the National Institutes of Health to support these efforts.

Dr. Axelrad is a member of multiple international gastrointestinal societies, is involved in IBD guideline development and educational programs, and serves on the editorial boards of multiple journals. He leads multiple clinical trials and international registries, and mentors trainees in various research activities. Dr. Axelrad has also received several awards for his work including the Auxiliary of the American College of Gastroenterology Award and Dr. Philip Moskowitz Prize in Autoimmunity.

Last, Dr. Axelrad is a vocal IBD patient advocate, living with Crohn's disease since his teenage years. He has shared his journey at patient symposia and webinars, on the Crohn's and Colitis Foundation website, and across social media platforms, to encourage patient engagement and empowerment.

In 2024, Dr. Axelrad received the Sherman Emerging Leader Prize for Excellence in Crohn's and Colitis.